Abstract
A review of 1134 patients from the John Wayne Cancer Clinic with melanoma metastatic to regional lymph nodes was carried out to evaluate the importance of various prognostic features after lymphadenectomy. Univariate analysis identified the prognostic significance of clinical stage for lesions with a depth of 0.76 to 4.0 mm (p = 0.0018); number of involved nodes (p = 0.0001); Breslow's thickness (p = 0.0487); gender (p = 0.0103); location on an extremity (p = 0.0104); synchronous versus asynchronous detection of nodal metastases (p = 0.0107); age as a continuous variable (p = 0.0670); and unknown primary site (p = 0.088). Multifactorial analysis showed that number of involved nodes (p = 0.0001), extremity location of primary (p = 0.0059), and Breslow thickness (p = 0.0334) maintained their significance, whereas gender (p = 0.0627) and clinical stage (p = 0.0942) were almost significant. The long-term survival of the entire patient population at 5, 10, and 15 years of follow-up was estimated to be 46%, 41%, and 38%. When individual characteristics found to be significant by multivariate analysis were combined into different subsets, there was considerable heterogeneity, with 5-year survival varying from 79% to 14%. To quantify this heterogeneity better, a mathematical model was developed and found to approximate closely the observed survival rates in the heterogenous subsets and in the group as a whole.
MeSH Terms
Analysis of Variance
Female
Follow-Up Studies
Humans
Lymph Node Excision/methods
Lymph Nodes/pathology
Lymphatic Metastasis
Male
Mathematics
Melanoma/mortality,pathology,secondary,surgery
Models, Theoretical
Multivariate Analysis
Neoplasm Staging
Prognosis
Retrospective Studies
Skin Neoplasms/mortality,pathology,surgery
Survival Rate
Time Factors
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Morton D L
John Wayne Cancer Clinic, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine.
Wanek L
Nizze J A
Elashoff R M
Wong J H
References (26)
26 references, click to expand
-
Demonstration in sarcoma patients of anti-tumor antibodies which fix only human complement.
Nature. 1970 Mar 21;225(5238):1137-8
PMID: 4984865
-
Current management of malignant melanoma.
Ann Surg. 1990 Aug;212(2):123-4
PMID: 2375644
-
BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
Ann Surg. 1974 Oct;180(4):635-43
PMID: 4412271
-
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs.
N Engl J Med. 1977 Sep 22;297(12):627-30
PMID: 895764
-
A rational approach to the surgical management of melanoma.
Ann Surg. 1977 Oct;186(4):481-90
PMID: 907393
-
Comparison of the classification by microscopic level (stage) of malignant melanoma by three independent groups of pathologists.
Cancer. 1977 Dec;40(6):3112-4
PMID: 589569
-
A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results.
Cancer. 1978 Mar;41(3):948-56
PMID: 638981
-
Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
Aust N Z J Surg. 1978 Feb;48(1):49-52
PMID: 276348
-
The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study.
Surgery. 1978 Nov;84(5):626-32
PMID: 715678
-
Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning.
Surg Forum. 1977;28:147-8
PMID: 617400
-
Malignant melanoma of the head and neck.
Head Neck Surg. 1978 Nov-Dec;1(2):123-8
PMID: 755804
-
Altered lymphatic drainage following lymphadenectomy.
Cancer. 1980 Jun 15;45(12):3045-9
PMID: 7388748
-
A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).
Ann Surg. 1981 Mar;193(3):377-88
PMID: 7212800
-
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities.
Cancer. 1982 Jun 1;49(11):2420-30
PMID: 7074555
-
Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.
Ann Surg. 1982 Jul;196(1):69-75
PMID: 7092355
-
Results of ilioinguinal dissection for stage II melanoma.
Ann Surg. 1982 Aug;196(2):180-6
PMID: 7092368
-
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma.
Ann Surg. 1983 Sep;198(3):379-85
PMID: 6615058
-
Prognosis of patients with pathologic stage II cutaneous malignant melanoma.
Ann Surg. 1985 Jan;201(1):103-7
PMID: 3966826
-
Malignant melanoma prognostic factors 7: elective lymph node dissection.
J Dermatol Surg Oncol. 1985 Mar;11(3):233-9
PMID: 3882797
-
Suppressor cell activity in melanoma-draining lymph nodes.
Cancer Res. 1987 Mar 15;47(6):1529-33
PMID: 2949828
-
Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site.
Arch Surg. 1987 Dec;122(12):1380-3
PMID: 3689112
-
The role of elective lymph node dissection in melanoma: rationale, results, and controversies.
J Clin Oncol. 1988 Jan;6(1):163-72
PMID: 3275746
-
Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study.
Am J Surg Pathol. 1988 Aug;12(8):612-8
PMID: 3041850
-
Histomorphometry in the assessment of prognosis in stage II malignant melanoma.
Am J Surg Pathol. 1989 Jul;13(7):600-4
PMID: 2735491
-
Tumor-associated antigen immune complexes. A potential marker of recurrent melanoma.
Arch Surg. 1990 Feb;125(2):187-91
PMID: 2302059
-
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
Ann Surg. 1970 Nov;172(5):902-8
PMID: 5477666